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1. Introduction 
A number of reports have described elevated lev- 
els of tRNA methylase activities in a variety of tumor 
tissues when compared with normal control tissues 
[e.g., l-41. Such elevated methylase activities may 
be due to elevated levels of the enzymes themselves 
or also to the absence of methylase inhibitors [5-71. 
Whether changes in methylase activity are always ac- 
companied by parallel changes in the base composi- 
tion of tumor tRNA has been studied considerably 
less than the properties of the enzymes. Berquist and 
Matthews [8] have reported elevated levels of some 
methylated purines in tRNA from a mammary ade- 
nocarcinoma and S 180 ascites tumor in mice. Viale 
and co-authors [9, lo] have reported substantially 
elevated levels of methylated purines as well as py- 
rimidines in tRNA from human brain tumors when 
compared with normal brain. Data published by Iwa- 
nami and Brown [ 1 I] for HeLa cell and L cell tRNA 
and by Baguley and Staehelin [ 121 for a transplant- 
able rat leukemia, on the other hand, appear to be 
similar to minor base composition data reported for 
mammalian liver [ 12, 131 . Indirect evidence for al- 
tered tRNA species in tumors is provided by investi- 
gations of the chromatographic behavior of tRNA 
charged with radioactive amino acids [e.g. 14-161. 
The function of the modified bases in tRNA is 
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still rather obscure. tRNAflY from Staph. epidermidis 
participating in peptidoglycan synthesis, but incapable 
of participating in protein synthesis or binding to ri- 
bosomes, contains no modified bases other than 4- 
thiouridine [ 171. This result points to a major role 
of tRNA modification in the overall process of pro- 
tein synthesis. 
In order to answer the question of whether sub- 
stantial changes in tRNA structure are generally 
characteristic for the neoplastic state systematic anal- 
ytical studies are required which, in view of the small 
amounts of tissue available in many instances, have 
to utilize ultrasensitive methodology. Methods de- 
veloped recently in this laboratory [ 18, 191 make 
use of the fact that accurate quantitative base com- 
position analysis of RNA can be carried out by chem- 
ical incorporation of tritium label into periodate- 
oxidized enzymatic digests of RNA. 
We have recently used this procedure in a sys- 
tematic investigation of the base composition of 
tRNA isolated from various normal and neoplastic 
mammalian tissues. This communication reports on 
the minor base composition of tRNA isolated from 
normal human brain as well as from malignant brain 
tumors. 
2. Materials and methods 
Brain tumor specimens, as well as normal con- 
tiguous tissue, were obtained from Professor W.H. 
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Sweet and Mrs. J. Messer, Department of Neuro- 
surgery at the Massachusetts General Hospital. The 
tissues were kept on ice for less than one hour after 
removal and then immediately frozen between blocks 
of dry ice. Normal human brain tissue from the right 
frontal lobe of a 39-year-old patient whose death 
was caused by a cardiovascular disease not involving 
the brain was obtained from the Department of 
Pathology at the Massachusetts General Hospital 
within four hours post mortem. tRNA was isolated 
by direct phenol extraction [20,21]. Yields of RNA 
were about 100 pg per g of normal brain tissue and 
about 250 pg per g of neoplastic tissue. RNA pre- 
parations were subjected to acrylamide gel elec- 
trophoresis [22] to check for impurities. RNA was 
digested to nucleosides as described previously [ 18, 
191. Aliquots of such digests were subjected to 
periodate oxidation and treatment with tritium la- 
beled borohydride. Following two-dimensional thin- 
layer chromatography and film detection [23] the 
labeled nucleoside derivatives were assayed by liq- 
uid scintillation counting. The minor base composi- 
tion was determined according to the equation [ 191 : 
where fi is the base composition expressed as moles 
of an individual nucleoside/moles of all minor nu- 
cleosides (number = N) determined. By setting the 
N 
total count rate ic= lcpmi equal to 100 the base compo- 
sition is expressed as the percentage of the total. 
3. Results 
Table 1 presents data on the relative distribution 
of twelve minor bases in unfractionated tRNA iso- 
lated from normal human brain and a glioblastoma 
multiforme. The normal tissue was obtained at auto- 
psy four hours post mortem (see above). Analysis of 
a fresh surgical specimen (normal tissue adjacent to 
an astrocytoma) resulted in base distribution data 
identical to those presented in column 1 of table 1 
[24]. The minor base composition obtained from the 
brain tumor specimen is almost identical to its normal 
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counterpart (table 1). Minor differences in the values 
for dihydrouridine,N’-methylguanosine, and pseu- 
douridine appear, however, to be statistically sig- 
nificant. Very similar or identical base distribution 
data were obtained from six additional surgical 
specimens of glioblastoma multiforme, as well as 
from three specimens of astrocytoma, a more slowly 
growing brain tumor. Standard deviations for most 
minor bases are low (table 1). The higher relative 
standard deviation for m6A is due to the highRf 
value of m6 A trialcohol in both chromatographic 
dimensions resulting in a somewhat diffuse spot of 
this compound. Because mammalian tRNA appears 
to contain no m6A [ 11, 251 - its presence being 
due to a rearrangement of m1 A [26] - the sum 
(m’ A + m6 A) probably reflects the true m’ A con- 
tent of the RNA. The high standard deviation for 
inosine is caused by the close proximity of guanosine 
on the chromatographic map, which makes accurate 
cutting out of the inosine trialcohol spot sometimes 
difficult. 
In table 2 our results are compared with minor 
base distribution data for HeLa cell tRNA reported 
by Iwanami and Brown [ 1 l] as well as for normal 
human brain and glioblastoma multiforme tRNA 
reported by Viale [lo] . It can be seen that our re- 
sults are in close agreement with data reported by 
Iwanami and Brown for HeLa cell tRNA. Similar 
results for some of these minor bases were published 
by Baguley and Staehelin [ 121 for rat liver and leu- 
kemic spleen tRNA and by Graddock [27] for rat 
liver and intestine as well as for rat liver after treat- 
ment with chemical carcinogens. Our data for brain 
tRNA also resemble the rat liver values for m5 C, 
m1 G, m’ A, and \k reported earlier by Dunn [ 131. 
These authors have used methods completely dif- 
ferent from our isotope derivative method, namely, 
labeling with methionine-methyl-i4C, both in tis- 
sue culture [ 1 l] and in whole animals [27] , fol- 
lowed by chromatographic and counting techniques, 
and alkaline hydrolysis of nonradioactive RNA fol- 
lowed by chromatography and spectrophotometry 
[ 12, 131 . There is, however, disagreement between 
our minor base distribution data and those published 
by Viale and co-workers, particularly for mr G and 
m5 C in normal brain tRNA, but also for other bases 
in normal control tissue as well as the tumor (table 
2). 
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Table 1 
Minor base composition of unfractionated tRNA from normal human brain and a malignant brain tumor (glioblastoma multi- 
forme)*. 
m’A 
m6A 
m1A+m6A 
hU 
m:G 
mZG 
m’G$ 
m’G 
m3C$ 
msC 
J, 
m5 U (rT) 
I 
Normal brain Srel * * * Glioblastoma srel 
*** 
(%) + s** (%) multiforme (%) + s** (%) 
7.50 f 0.10 1.36 7.22 * 0.07 0.96 
1.94 r 0.07 3.63 1.87 * 0.12 6.42 
9.44 + 0.12 1.25 9.09 * 0.17 1.82 
19.65 k 0.37 1.88 18.07 * 0.27 1.51 
4.39 f 0.10 2.22 4.27 * 0.15 3.55 
10.19 f 0.25 2.43 10.89 f 0.30 2.79 
+ 0.14 f 3.68 3.91 3.79 0.19 5.13 
5.47 f 0.22 4.04 5.30 * 0.19 3.49 
1.79 + 0.07 3.80 1.87 -r 0.04 1.91 
14.28 f 0.21 1.45 14.13 * 0.26 1.84 
24.04 * 0.29 1.21 25.66 * 0.15 0.57 
4.89 + 0.10 1.98 4.96 f 0.07 1.31 
2.16 + 0.23 10.63 1.96 f 0.25 12.71 
Sum 99.98% 99.99% 
* Data are expressed as percentages of the total minor base composition. 
** Standard deviation (N = 6). 
*** Relative standard deviation sreJ = s X loo/mean %. 
$ Recoveries of m’G and m3C as tritium labeled trialcohols are about 70% and 85%, respectively. Our data are not corrected 
for incomplete recovery of these compounds. 
Table 2 
A comparison of our minor base distribution data with results reported by others for tRNA isolated from human cells *. 
HeLa 
cells [ 111 
Our data Normal human Our 
(normal brain) brain [lo] data 
Glioblastoma 
multiforme [ lo] 
Our 
data 
m’A+m6A 18.27 17.44 2.67 12.61 10.15 11.92 
hU n.r.** n.r.** - n.r.** - - 
m:G 8.02 8.11 8.00 5.86 10.06 5.60 
m*G 15.90 18.83 4.74 13.61 16.56 14.28 
m’G 6.96 6.80 n.r.** - n.r.** _ 
m’G 8.67 10.11 0.30 7.31 14.07 6.95 
m3C 4.34 3.31 n.r.** _ n.r.** _ 
m5C 28.25 26.38 1.78 19.08 6.41 18.53 
J, n.r.** - 74.81 32.11 34.37 33.65 
m5 U (rT) 9.59 9.03 4.74 6.53 5.52 6.50 
I n.r.** _ 2.96 2.89 2.85 2.57 
Sum 100.00% 100.01% 100.00% 100.00% 99.99% 100.00% 
* Data of others were calculated from values published by Iwanami and Brown [ 1 l] and Viale [lo]. Our data were recal- 
culated to account for the fact that values for certain minor bases had not been reported by these authors. 
** Not reported. 
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4. Discussion 
The data reported in this communication reveal 
only minor differences between the overall minor 
base composition of normal human brain and brain 
tumor tRNA. In addition to differences in minor 
base composition there are differences in the rela- 
tive proportions of the major bases between normal 
brain and brain tumor tRNA [28] : brain tRNA is 
richer in uridine than glioblastoma or normal liver 
tRNA. The low uridine content of glioblastoma 
tRNA may, however, be unrelated to the neoplas- 
tic process itself because tRNA isolated from other 
tumors (e.g., a chromophob adenoma of the pitu- 
itary) was found to contain relatively high amounts 
of uridine [28]. In no instance, thus far, have we 
obtained evidence for an increase in the ratio 
mole % of modified bases/mole% of major bases, i.e. 
for an actual ‘hypermethylation’ or ‘hypermodifica- 
tion’ of human brain tumor tRNA. 
The question of whether or not alterations of 
tRNA are characteristic or responsible for the neo- 
plastic transformation cannot be decided at the 
present time. In view of the central role of tRNA 
in the translation of the genetic code [e.g., 291 ,even 
minor modifications of single species may profoundly 
influence the pattern of protein synthesis and the 
response of the cell to humoral factors regulating 
growth. 
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